Dr. Nelson P. Kopyt, DO

Medicare patients and services

Medicare patients, 2024

328

Services billed

1,488

Patients’ average age

75

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 21 companies reported 165 payments worth $125,015 in total to this clinician.

What the payments were for

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Pennsylvania →

Industry-funded research

Named as a principal investigator on 8 industry-funded studies in 2025, from 5 companies. The companies reported $110,539 in research payments for these studies, mostly to the institutions running them.

• The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
  Eli Lilly and Company · Active, not recruiting · NCT06383390
• A Randomised,Double Blind,Placebo Controlled,Parallel Group Study to Assess the Efficacy and Safety of Baxdrostat in Participants with Uncontrolled Hypertension on Two or More Medications including Participants with R…
  AstraZeneca Pharmaceuticals LP
• ANCHOR Study: A Study to Assess the Safety and Efficacy of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
  AbbVie Inc. · Recruiting · NCT06902558
• TA description Cardiovascular Renal and Metabolism Indications Chronic Kidney Disease Study status Ongoing Phase descripton Phase 3 Category R&D Sponsored Delivery model Internal
  AstraZeneca Pharmaceuticals LP
• A randomized, double-blind, placebo-controlled, parallel-group, multicenter Phase 3 study to investigate the efficacy and safety of FInerenone, in addition to standard of care, on the progression of kidney disease i…
  Bayer HealthCare Pharmaceuticals Inc.
• BAY 948862, A randomised, double-blind, placebo-controlled, parallel-group, multicentre Phase 3 study to investigate the efficacy and safety of Finerenone, in addition to standard of care, on the progression of kidney…
  Bayer HealthCare Pharmaceuticals Inc.
• A Study to Assess Adverse Events and Effectiveness of IntraVenous Infusions of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
  AbbVie Inc.
• A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Atrasentan in Patients With IgA Nephropathy at Risk of Progressive Loss of Renal Function
  Novartis Pharmaceuticals Corporation

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Nephrology (Kidney) clinicians in Allentown

• Siraj Ahmed, MD
• Tayyab Ali, MD
• Syed Ali Aown, M.D
• Satyam Arora, D.O.
• Jose Avila
• Swomya P. Bal, MD
• Ravindra Bollu, M.D.
• Guillermo E. Carnero Salazar, M.D.